Rec-h-FGF19 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 94 | Primary sclerosing cholangitis | 2 |
94. Primary sclerosing cholangitis
Clinical trials : 148 / Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-003392-30-NL (EUCTR) | 02/05/2016 | 17/12/2015 | The testing of NGM282 for 12 weeks in patients with Primary Sclerosing Cholangitis (PSC) | A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) | PRIMARY SCLEROSING CHOLANGITIS (PSC) MedDRA version: 19.0;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders MedDRA version: 19.0;Level: HLT;Classification code 10004607;Term: Bile duct infections and inflammations;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;Level: PT;Classification code 10008609;Term: Cholangitis sclerosing;Level: HLGT;Classification code 10004606;Term: Bile duct disorders;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: NGM282 INN or Proposed INN: engineered recombinant human FGF19 Other descriptive name: rec-h-FGF19 Product Name: NGM282 INN or Proposed INN: engineered recombinant human FGF19 Other descriptive name: rec-h-FGF19 | NGM Biopharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | France;United States;Netherlands;United Kingdom | ||
| 2 | EUCTR2015-003392-30-GB (EUCTR) | 18/04/2016 | 14/12/2015 | The testing of NGM282 for 12 weeks in patients with Primary Sclerosing Cholangitis (PSC) | A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) | PRIMARY SCLEROSING CHOLANGITIS (PSC) MedDRA version: 19.0;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders MedDRA version: 19.0;Level: HLT;Classification code 10004607;Term: Bile duct infections and inflammations;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;Level: PT;Classification code 10008609;Term: Cholangitis sclerosing;Level: HLGT;Classification code 10004606;Term: Bile duct disorders;System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: NGM282 INN or Proposed INN: engineered recombinant human FGF19 Other descriptive name: rec-h-FGF19 Product Name: NGM282 INN or Proposed INN: engineered recombinant human FGF19 Other descriptive name: rec-h-FGF19 | NGM Biopharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 60 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;United States;Netherlands;United Kingdom |